RHOBTB2-Related Developmental and Epileptic Encephalopathy (DEE64) — Comprehensive Research Report

1. Disease Information

Overview. RHOBTB2-related developmental and epileptic encephalopathy (also designated Developmental and Epileptic Encephalopathy 64, DEE64; formerly Early Infantile Epileptic Encephalopathy 64, EIEE64) is a rare, autosomal dominant neurodevelopmental disorder caused by heterozygous, almost always de novo, missense variants in RHOBTB2 (Rho-related BTB domain-containing protein 2). It was first delineated in 2018 and is characterized by early-onset (usually first-year-of-life) seizures, moderate-to-severe intellectual disability, postnatal microcephaly, hypotonia, and a distinctive polymorphic movement disorder with paroxysmal, alternating-hemiplegia-of-childhood (AHC)-like features (dystonia, ataxia, chorea-like movements) (Straub et al. 2018, PMC5777381; OMIM #618004). The disease spectrum has since expanded to include milder phenotypes from GTPase-domain variants and biallelic loss-of-function variants, so the field increasingly uses the umbrella term "RHOBTB2-related disorders" (RHOBTB2-RD) rather than a single DEE label (Genetics in Medicine 2023; Epilepsia 2026, epi.70286).

Key identifiers:

Synonyms/alternative names: RHOBTB2-related developmental and epileptic encephalopathy; Early Infantile Epileptic Encephalopathy 64 (EIEE64) — older nomenclature; RHOBTB2-related disorders (RHOBTB2-RD, encompassing DEE64 plus the milder GTPase-domain and biallelic-variant phenotypes); the protein/gene is also known by the alias DBC2 ("Deleted in Breast Cancer 2") and p83.

Evidence basis: Nearly all published knowledge derives from aggregated case series and case reports (patient-level clinical, EEG, MRI, and genetic data), i.e., disease-level literature rather than large-scale EHR aggregation. The largest cohort to date integrates 12 Chinese patients with 79 previously published international cases (~91 total) (Epilepsia 2026); earlier landmark series include the original 10-patient description (PMC5777381), a 34-patient early series, and the 11-patient AHC-spectrum expansion (Zagaglia et al. 2021, Neurology).

2. Etiology

Disease causal factor: Monogenic — heterozygous, predominantly de novo missense variants in RHOBTB2, an atypical Rho GTPase family gene (8p21.3). No environmental or infectious causal factor is implicated; this is a purely genetic (Mendelian) disorder within dismech's "Mendelian" category classification.

Genetic risk factors: - Causal variants: De novo heterozygous missense variants clustering in the two BTB (Broad-complex, Tramtrack, Bric-à-brac) domains — hotspots at Arg483 (p.Arg483His, recurrent) and Arg511 (p.Arg511Trp, p.Arg511Gln, p.Arg511Gly, all recurrent) account for "more than half" of reported BTB-domain variants (PMC11744465; Epilepsia 2026, reporting 75% of Chinese-cohort variants in the BTB domain with p.Arg483His as a conserved hotspot). Other BTB-region variants include p.(Ala471Val), p.(Ala474Gly), p.(Arg507Cys), p.(Arg489Trp) — the latter confirmed de novo in the French Guiana case report (Defo et al. 2022, PMC9184662). - A second class of variants affects the N-terminal GTPase domain — e.g., p.(Asp114His), p.(Arg116Cys), p.(Arg154Gln), p.(Arg154Leu) — and is mechanistically and phenotypically distinct (see §6). - Biallelic (recessive) variants: Homozygous/compound-heterozygous splice-site and truncating variants (e.g., p.(Ser543Alafs52)) have been described in 9 families, showing that complete loss of RHOBTB2 function is also pathogenic, producing "variable neurodevelopmental phenotypes" distinct from the dominant gain-of-function BTB presentation (GIM 2023). - Constraint metrics (gnomAD pLI/LOEUF/missense-Z) could not be retrieved directly in this session (page was JS-rendered); prior functional work notes ExAC-era constraint data suggested RHOBTB2 tolerates loss-of-function variants, arguing against simple haploinsufficiency as the dominant-disease mechanism (PMC5777381) — consistent with the biallelic-LOF-vs-dominant-missense dichotomy above. This should be independently verified against the current gnomAD v4 browser before curation. - Modifier genes: None specifically established; CEBPA* has been proposed as an upstream transcriptional regulator of RHOBTB2 expression in a rat prenatal-malnutrition model (see §15), but this is not a human disease modifier per se.

Environmental risk/trigger factors: Not causal, but recognized precipitants of acute encephalopathic/seizure exacerbation in already-affected individuals: - Fever/hyperthermia — recurring trigger for acute encephalopathy and status epilepticus episodes. - Head trauma (including mild) — documented as a trigger for acute encephalopathy in RHOBTB2 patients (Neurology Genetics, "Acute encephalopathy after head trauma in a patient with a RHOBTB2 mutation"; Neurología English Edition, "Mild head trauma: Acute encephalopathy trigger..."). At least five patients across the literature have had acute encephalopathy/seizures triggered by hyperthermia or head trauma, with severe EEG abnormalities and abnormal MRI (hemisphere swelling, restricted diffusion) during these episodes.

Protective factors: None identified in the literature reviewed.

Gene-environment interactions: The fever/trauma-triggered encephalopathy pattern suggests a gene-environment interaction in which the already-destabilized RHOBTB2 protein/ion-channel network has reduced tolerance for physiological stress, but no formal GxE study has been published.

3. Phenotypes

Core clinical features (with suggested HPO terms; frequencies drawn from the literature reviewed — verify against the largest cohort, Epilepsia 2026, for precise percentages before final curation)

Genotype-linked phenotype severity (see also §6, §9): - BTB-domain variants → earlier seizure onset, more severe DEE, drug-resistant epilepsy, and the full AHC-like movement disorder. - GTPase-domain variants → broader, generally milder spectrum: mild-to-moderate intellectual disability, learning difficulties, developmental regression in some, and — per the mechanistic study below — seizures that are typically better controlled with antiseizure medication (HMG 2025, PMC/Oxford Academic; GIM 2023). - Biallelic loss-of-function variants → variable neurodevelopmental phenotypes distinct from the classic dominant BTB presentation. - A milder phenotype was also correlated with a specific variant, p.(Ala474Gly), in the original ten-patient cohort (PMC5777381).

Quality of life impact: No disease-specific EQ-5D/SF-36/PROMIS data were located. Qualitatively, the combination of drug-resistant epilepsy, severe intellectual disability, and a debilitating paroxysmal movement disorder (with episodic AHC-like crises) is described as substantially disabling, with motor function ranging "from total lack of head control and inability to walk to walking with a broad-based or unsteady gait" (Frontiers Pediatrics 2024).

4. Genetic/Molecular Information

Causal gene: RHOBTB2 (HGNC:18756; NCBI Gene 23221; Ensembl ENSG00000008853; OMIM *607352). Encodes an atypical Rho GTPase with a modular architecture: N-terminal GTPase domain, proline-rich region, tandem BTB1–BTB2 domains, and a conserved C-terminal region (Wikipedia/HGNC; RhoBTB family review).

Pathogenic variant classification and type: - Predominantly de novo heterozygous missense variants, clustering in the BTB1/BTB2 domain region (dominant, gain-of-function-like mechanism) or the N-terminal GTPase domain (distinct, milder mechanism). - Recurrent/hotspot residues: Arg483 and Arg511 (BTB domain) — collectively >50% of BTB variants. - Documented BTB-domain variants: p.(Ala471Val), p.(Ala474Gly), p.(Arg483His), p.(Arg489Trp), p.(Arg507Cys), p.(Arg511Gly), p.(Arg511Trp), p.(Arg511Gln), p.(Ser543Alafs52 — homozygous/biallelic). - Documented GTPase-domain variants: p.(Asp114His), p.(Arg116Cys), p.(Arg154Gln), p.(Arg154Leu). - Biallelic (recessive) variants: splice-site and truncating variants reported in 9 families (GIM 2023), establishing complete loss-of-function as a second, distinct disease mechanism. - ACMG/ClinVar classification: individual variants (e.g., c.1465C>T p.(Arg489Trp), ClinVar RCV000656374) are classified case-by-case; consult ClinVar/ClinGen directly for current classifications before curation. - Allele frequency: Pathogenic variants are essentially absent from population databases (gnomAD) consistent with de novo, severe, dominant disease — exact gnomAD constraint values (pLI/LOEUF) should be pulled directly from the gnomAD browser (not confirmed in this session due to a fetch limitation). - Somatic vs. germline: Germline (constitutional) de novo variants for DEE64; separately, somatic* loss-of-function/deletion events in RHOBTB2 are described in cancer (see below) — these are a biologically related but clinically distinct phenomenon.

Functional consequence — the central genotype-mechanism finding:

"Mutant RHOBTB2 was more abundant than the wild-type, most likely because of impaired degradation in the proteasome" — and this effect was reversed by proteasome inhibition, "confirming proteasomal degradation impairment as the primary mechanism" for BTB-domain variants (Straub et al. 2018, PMC5777381).

This is a gain-of-function / dominant-negative-like accumulation mechanism (increased mutant protein abundance due to impaired 26S proteasomal degradation), not simple haploinsufficiency — a genuinely unusual, notable mechanism among developmental encephalopathy genes. Co-immunoprecipitation studies found no differential CUL3 binding between mutant and wild-type RHOBTB2, indicating the pathogenic effect operates downstream of/independent from simple loss of CUL3 engagement (PMC5777381).

By contrast, GTPase-domain variants do not impair proteasomal degradation — RHOBTB2 protein levels remain normal — pointing to an alternative (likely direct protein-protein-interaction or GTPase-cycle) pathogenic mechanism.

Epigenetic information: In cancer contexts (not DEE), RHOBTB2 promoter CpG-island hypermethylation causes epigenetic silencing and loss of tumor-suppressor function (see §6). No epigenetic mechanism has been specifically described for the DEE64 phenotype.

Chromosomal abnormalities: No recurrent large-scale chromosomal rearrangement (translocation, aneuploidy) is described for DEE64; disease is driven by point/small-indel variants within RHOBTB2.

5. Environmental Information

• Environmental/toxin factors: None established as causal for RHOBTB2-RD; disease is monogenic.
• Lifestyle factors: Not applicable as causal factors; however, avoidance of known triggers (fever control, minimizing head trauma risk) is a practical management consideration given the documented trigger relationship (§2).
• Infectious agents: Not causal, but febrile illness (of any infectious etiology) is a recognized trigger for acute encephalopathic crises in affected individuals, not a cause of the underlying genetic disease.

6. Mechanism / Pathophysiology

Molecular function of RHOBTB2 (baseline biology)

RHOBTB2 (a.k.a. DBC2) is a substrate-specific adaptor for a Cullin-3 (CUL3)–RBX1-based E3 ubiquitin ligase complex (Wilkins et al., PMC2749729; Berthold et al., "RhoBTB2 is a substrate of the mammalian Cul3 ubiquitin ligase complex"). Mechanism: 1. RHOBTB2's BTB domains bind CUL3's N-terminal region. 2. RHOBTB2 recruits specific substrates for ubiquitination. 3. RBX1 recruits E2 ubiquitin-conjugating enzymes, transferring ubiquitin to the CUL3/RHOBTB2-bound substrate, building a polyubiquitin chain. 4. The polyubiquitinated substrate — and RHOBTB2 itself — is degraded by the 26S proteasome. 5. An autoregulatory mechanism exists: the non-GTP-binding GTPase domain can fold back and interact intramolecularly with the BTB region, keeping RHOBTB2 in an inactive, degradation-protected state — a proposed "closed" conformation model.

Suggested GO terms: GO:0004871 (signal transducer activity — for GTPase-domain function); GO:0031624 (ubiquitin conjugating enzyme binding); GO:0031461 (cullin-RING ubiquitin ligase complex); GO:0043161 (proteasome-mediated ubiquitin-dependent protein catabolic process); GO:0007015 (actin filament organization); GO:0016477 (cell migration).

Causal chain for DEE64 (BTB-domain, dominant/gain-of-function arm)

1. Trigger: De novo missense variant at a BTB-domain hotspot (e.g., p.Arg483His, p.Arg511Trp/Gln/Gly).
2. Molecular lesion: Variant impairs proteasomal recognition/degradation of RHOBTB2 without disrupting CUL3 binding → increased steady-state abundance of mutant RHOBTB2 protein in neurons.
3. Downstream transcriptional/ion-channel effect: RNA-seq in a Drosophila overexpression model shows enrichment for differentially expressed ion channel genes, including orthologs of human voltage-gated sodium channels (paralytic → SCN1A/SCN2A/SCN3A/SCN8A), a potassium channel (slowpoke → KCNMA1/BK channel), and an ionotropic glutamate receptor (ir76a) (Human Molecular Genetics 2025).
4. Cellular electrophysiology (human iPSC-derived neurons): Neurons carrying patient BTB-domain variants show significantly altered neuronal excitability — increased action-potential firing frequency, increased AP half-width, and decreased depolarization speed — compared to wild-type. Critically, this electrophysiological derangement was not seen in neurons with GTPase-domain variants or with complete RHOBTB2 knockout, mechanistically explaining the BTB-vs-GTPase genotype-phenotype divergence.
5. Organismal phenotype (Drosophila): Pan-neuronal RhoBTB overexpression causes bang-sensitivity (seizure-like paralysis after mechanical shock) and severe locomotor impairment in negative-geotaxis assays; RhoBTB knockdown in dendritic arborization (da) neurons causes reduced dendritic branch number — implicating RHOBTB2 dosage in both neuronal excitability and dendritic morphogenesis (Straub et al. 2018, PMC5777381).
6. Clinical manifestation: Neuronal hyperexcitability + disrupted dendritic architecture → seizures, developmental encephalopathy, movement disorder.

Two candidate mechanistic hypotheses remain open (not yet distinguished): (a) RHOBTB2 accumulation indirectly dysregulates ion-channel gene transcription; (b) RHOBTB2 (or a RHOBTB2-CUL3 complex) directly ubiquitinates ion channels as substrates, and impaired turnover/mistargeting of the channels themselves drives hyperexcitability.

Cell types/anatomical scale: Primarily central nervous system neurons (cortical/dendritic-arborization-type neurons in the fly model; iPSC-derived cortical neurons in the human model). Suggested CL terms: CL:0000540 (neuron); CL:0000598 (dendritic cell — not relevant, exclude); CL:0011020 (neural progenitor cell, if precursor-stage effects are modeled); consider CL:0000679 (glutamatergic neuron) given the ionotropic glutamate receptor link.

Cancer-associated mechanism (contrast arm — informs the "gain vs. loss" duality)

In sporadic cancers, loss of RHOBTB2 function — via deletions, loss-of-function variants (found in ~10% of breast cancer samples), or CpG-island promoter hypermethylation — removes its tumor-suppressor activity (failure to degrade oncogenic substrates such as Cyclin D1), promoting unchecked proliferation in breast, lung, bladder, gastric cancers, and osteosarcoma (Frontiers Pediatrics 2024; Oncogene 2016, DBC2/RhoBTB2-Musashi-2 axis). This is the biological converse of the DEE64 mechanism: precise RHOBTB2 dosage is essential — too little predisposes to malignancy, too much (via impaired degradation) is neurotoxic.

Additional hypothesized pathway: dysregulation of an E2F1–RHOBTB2 axis affecting apoptotic signaling has been proposed as contributing to the neurodevelopmental phenotype and was leveraged in an AI-guided drug-repurposing screen (see §12).

Metabolic/immune involvement: No specific metabolic pathway or immune-mediated mechanism has been reported for RHOBTB2-RD; this is a cell-intrinsic proteostasis/ion-channel-excitability disorder of the CNS.

Molecular profiling data: RNA-seq (Drosophila overexpression model) is the principal transcriptomic dataset reported; no human patient-derived multi-omics (proteomics, metabolomics, single-cell) datasets specific to RHOBTB2-RD were identified in this search.

7. Anatomical Structures Affected

Organ level: - Primary: Central nervous system (brain) — cerebral cortex (seizure generation, cognitive impairment), basal ganglia/extrapyramidal circuits (dystonia, chorea), cerebellum (ataxia). - Secondary: Growth (postnatal microcephaly, poor postnatal growth) reflects secondary CNS/systemic developmental effects rather than a distinct organ-level primary lesion. - Body systems: Nervous system (primary); musculoskeletal system secondarily affected via hypotonia/movement disorder.

Suggested UBERON terms: UBERON:0000955 (brain); UBERON:0001872 (cerebral hemisphere); UBERON:0002037 (cerebellum); UBERON:0002420 (basal ganglion).

Tissue/cell level: Cortical and dendritic-arborization neurons (per the Drosophila and iPSC modeling). RHOBTB2 tissue expression is reported as primarily neural, with lesser expression in fetal heart and lungs.

Subcellular level: Cytosol, plasma membrane, cytoskeleton (actin) per baseline RHOBTB2 biology (Wikipedia/UniProt); the ubiquitin-proteasome degradation machinery (26S proteasome) is a key subcellular locus of pathogenic mechanism. Suggested GO Cellular Component terms: GO:0005737 (cytoplasm); GO:0005886 (plasma membrane); GO:0015629 (actin cytoskeleton); GO:0000502 (proteasome complex).

Localization/lateralization: The characteristic AHC-like movement-disorder episodes are, by definition, often lateralized/alternating (hemiplegic episodes shifting sides), a distinguishing clinical feature from typical bilateral movement disorders.

8. Temporal Development

• Onset: Congenital/neonatal predisposition with clinical onset typically in the first year of life; seizures have been documented as early as 4 days postnatal in the most severe cases. Microcephaly is typically postnatal in onset (normal head circumference at birth in documented cases, e.g., the French Guiana patient, with microcephaly emerging by 9 months).
• Onset pattern: Acute-to-subacute onset of seizures; insidious emergence of developmental delay/regression.
• Progression: Variable — ranges from static severe DEE with drug-resistant epilepsy and profound motor/cognitive impairment (BTB-domain variants) to a milder, more static-to-slowly-progressive course with learning difficulties (GTPase-domain variants); some patients show frank developmental regression.
• Disease course pattern: Chronic, lifelong; punctuated by episodic/paroxysmal exacerbations — both the intrinsic AHC-like movement episodes and acute encephalopathic crises triggered by fever or head trauma.
• Critical periods: Infancy/early childhood is the period of highest vulnerability for seizure onset and encephalopathic crises; avoidance of febrile illness complications and head trauma is a practically important window for intervention (see §13).

9. Inheritance and Population

Epidemiology: RHOBTB2-RD is an ultra-rare disorder. Approximately 91 cases have been aggregated in the most recent comprehensive cohort (12 Chinese + 79 international) (Epilepsia 2026); earlier series reported 19–34 patients. No formal population-based prevalence or incidence estimate (per 100,000) has been published; RHOBTB2-related AHC-spectrum disease is grouped among ultra-rare neurological disorders generally estimated at 1:100,000–1:1,000,000 by analogy to related AHC etiologies, but this figure is not RHOBTB2-specific and should be treated as a rough proxy, not a citable disease-specific statistic.

Inheritance pattern: Autosomal dominant for the classic BTB-domain and GTPase-domain missense phenotypes, essentially always occurring as de novo variants (parental testing consistently negative in reported trios). A separate autosomal recessive (biallelic loss-of-function) inheritance pattern has been described in 9 families for splice-site/truncating variants (GIM 2023), producing a distinct, variable neurodevelopmental phenotype.

Penetrance/expressivity: Appears fully penetrant for the dominant missense variants (all reported carriers are symptomatic), with highly variable expressivity — phenotype severity ranges from classic severe DEE64 to milder learning-difficulty/movement-disorder-predominant presentations, correlating with variant domain location (BTB vs. GTPase) as detailed in §6.

Genetic anticipation: Not applicable/not reported — this is not a repeat-expansion disorder.

Germline mosaicism: Not specifically documented for RHOBTB2 in the sources reviewed; general possibility exists for any de novo dominant disorder but should be discussed with families as a theoretical (low) recurrence-risk consideration, not confirmed by RHOBTB2-specific mosaicism reports found here.

Founder effects / consanguinity: No founder-population effect reported for the dominant missense variants (occur as independent de novo events across diverse populations/ethnicities, including reports from France/French Guiana, China, UK, and elsewhere). The biallelic/recessive presentation would be expected to show increased likelihood in consanguineous families, consistent with general autosomal-recessive genetics, though this was not explicitly detailed in the sources reviewed.

Carrier frequency: Not applicable in the classical sense for a dominant de novo disorder (BTB/GTPase arm); for the recessive biallelic arm, population carrier frequency of individual loss-of-function alleles is expected to be very low (ultra-rare), consistent with a rare recessive disorder, but no specific carrier-frequency data were located.

Population demographics: Cases reported across multiple continents/ethnicities (European, Chinese, South American [French Guiana]) with no described geographic clustering or strong ethnic predisposition. Sex ratio: not clearly skewed in the sources reviewed (no strong male:female bias reported); should be checked against the largest published cohort (Epilepsia 2026) directly if precise ratios are needed for curation. Age distribution: pediatric-onset disorder by definition (first year of life), tracked through childhood in the reported literature (long-term adult natural history data are limited given the disorder's recent [2018] delineation).

10. Diagnostics

Clinical/laboratory tests: No RHOBTB2-specific biochemical biomarker has been identified; diagnosis is clinical + genetic. Standard metabolic/laboratory work-up is used mainly to exclude alternative etiologies of DEE.

Imaging: - Brain MRI is frequently normal, particularly early in the disease course (e.g., normal at both 3 and 10 months in the French Guiana case) — an important diagnostic point, since normal neuroimaging does not exclude RHOBTB2-RD. - During acute encephalopathic crises (fever/trauma-triggered), MRI can show transient abnormalities: hemisphere swelling and/or reduced diffusion in various brain regions.

Electrophysiology: - EEG findings are variable; documented findings include slowed background electrogenesis for age (delta rhythm) and diffuse/focal polyspikes (e.g., right-hemisphere polyspikes in the French Guiana case). During acute encephalopathic episodes, severe EEG abnormalities have been documented. - No RHOBTB2-specific EEG signature/biomarker (e.g., a pathognomonic ictal or interictal pattern) has been established.

Genetic testing (primary diagnostic modality): - Whole exome sequencing (WES) or whole genome sequencing (WGS), typically as a trio (proband + both parents) to confirm de novo status, is the standard diagnostic approach given the phenotypic heterogeneity and lack of a pathognomonic clinical sign. - Epilepsy/DEE gene panels that include RHOBTB2 are also used in clinical practice (e.g., Genomics England PanelApp lists RHOBTB2 under both "Early onset or syndromic epilepsy" and "Paroxysmal central nervous system disorders" panels). - Single-gene Sanger confirmation follows panel/WES identification of a candidate variant. - Chromosomal microarray, karyotyping, FISH, and mitochondrial DNA testing are not primary diagnostic tools for this disorder but are commonly part of a broader DEE diagnostic work-up to exclude other etiologies before/alongside RHOBTB2 sequencing.

Clinical diagnostic criteria: No formal consensus clinical diagnostic criteria (e.g., DSM/ICD-style) exist specifically for RHOBTB2-RD; diagnosis relies on the combination of characteristic phenotype (early-onset DEE + paroxysmal movement disorder ± AHC-like features + postnatal microcephaly) plus confirmatory molecular genetic testing.

Differential diagnosis: Most importantly, ATP1A3-related alternating hemiplegia of childhood (classic AHC), given phenotypic overlap in the paroxysmal movement-disorder domain — RHOBTB2-RD is explicitly framed in the literature as an AHC-mimicking/AHC-spectrum-expanding disorder distinct from ATP1A3-AHC ("RHOBTB2-Associated Neurological Phenotypes and Underlying Mechanisms: Alternating Hemiplegia of Childhood Beyond ATP1A3," Diseases journal). Other DEE genes (SCN1A, SCN2A, SCN8A, STXBP1, CDKL5, etc.) should be considered in the broader differential given phenotypic overlap in early-onset DEE.

Screening: No population-based newborn or carrier screening program exists for this ultra-rare de novo disorder; cascade/family screening is relevant primarily for the rare biallelic/recessive presentation.

11. Outcome/Prognosis

• Survival/mortality: No disease-specific mortality rate or life-expectancy data were located in the sources reviewed; RHOBTB2-RD is not classically described as directly life-limiting in the literature surveyed, though acute encephalopathic crises (fever/trauma-triggered, with severe EEG changes and MRI abnormalities) represent a recognized acute risk requiring urgent management.
• Morbidity/function: Substantial chronic morbidity from the combination of drug-resistant epilepsy, severe intellectual disability, and the paroxysmal movement disorder. Motor function outcomes span a wide spectrum — from complete lack of head control and non-ambulation to walking with a broad-based/unsteady gait — reflecting the broad genotype-driven severity spectrum.
• Complications: Acute encephalopathy episodes (fever- or trauma-triggered) with transient MRI/EEG abnormalities represent the most severe recognized complication category.
• Prognostic factors: The clearest identified prognostic determinant is variant location — BTB-domain variants predict earlier onset, more severe DEE, and drug-resistant epilepsy; GTPase-domain variants predict a milder, more variable course with better anti-seizure medication responsiveness. This genotype-phenotype correlation is the primary prognostic biomarker currently available (no molecular/biochemical prognostic biomarker has been validated).

12. Treatment

Pharmacotherapy (seizure management — current standard of care): Antiseizure medications are the mainstay, with the most frequently used agents being: - Valproic acid (CHEBI:39867) — NCIT: Pharmacotherapy (NCIT:C15986) - Levetiracetam (CHEBI:6437) - Topiramate (CHEBI:9366) - Oxcarbazepine (CHEBI:7824)

These were used, for example, in combination (triple therapy: topiramate + valproic acid + oxcarbazepine) in the French Guiana case, achieving partial but incomplete seizure control (PMC9184662). Explicitly noted limitation: "no treatments have been identified that address the other symptoms or the underlying pathophysiological mechanisms" — i.e., current therapy is purely symptomatic for seizures and does not target the movement disorder, cognitive impairment, or the proteasomal-degradation mechanism itself.

Pharmacogenomics: No RHOBTB2-specific pharmacogenomic (drug-metabolism) data were identified.

Emerging/experimental therapeutics: - AI-guided drug repurposing: A computational screen implicated NSAIDs — celecoxib (CHEBI:41423), diclofenac (CHEBI:47381), indomethacin (CHEBI:5773) — as potential RHOBTB2 pathway modulators, acting via downregulation of E2F1 (the hypothesized apoptotic-signaling axis noted in §6). This is preclinical/in-silico and not yet in clinical use (Frontiers Pediatrics 2024). - Antisense oligonucleotide (ASO) therapy targeting RHOBTB2 mRNA is described as "in development" — consistent with a rational precision-medicine approach given the gain-of-function/protein-accumulation mechanism (an ASO-mediated knockdown strategy would directly counter the pathogenic mechanism of excess mutant protein). No clinical trial identifier (NCT) was located for this program in the sources reviewed — this should be verified against ClinicalTrials.gov directly before curation, as no active registered trial was confirmed.

Surgical/interventional: No disease-specific surgical intervention (e.g., epilepsy surgery) was described as a standard approach in the literature reviewed, though it may be considered on a case-by-case basis for focal drug-resistant epilepsy as in general DEE management.

Supportive/rehabilitative care: Physical therapy, occupational therapy, and speech/communication therapy are inferred standard supportive management for the motor and speech impairments, consistent with general DEE management, though not explicitly detailed with RHOBTB2-specific outcome data in the sources reviewed. NCIT: Physical Therapy (NCIT:C15302); Rehabilitation (NCIT:C15315).

Treatment outcomes: Explicitly drug-resistant epilepsy is common; the disorder is generally refractory to standard antiseizure polytherapy in the more severe (BTB-domain) cases, while GTPase-domain-variant patients show comparatively better seizure control.

13. Prevention

Because RHOBTB2-RD arises from de novo germline variants with no known environmental causal contribution, classic primary prevention (risk-factor modification) is not applicable to preventing disease occurrence.

• Tertiary prevention (preventing complications in affected individuals): Given the documented fever- and head-trauma-triggered acute encephalopathy phenomenon, practical management should include prompt, aggressive fever control and head-injury precaution/avoidance counseling as a tertiary-prevention strategy to reduce acute encephalopathic crisis risk — this is directly supported by the trigger literature in §2, though no formal prospective prevention trial has validated this approach.
• Genetic counseling: Given the essentially universal de novo occurrence for the dominant missense variants, recurrence risk for future pregnancies in a family with an affected child is low (approximating general population risk, with residual risk from theoretical parental germline mosaicism) — standard genetic counseling practice for de novo dominant disorders. For the rare biallelic/recessive presentation, standard autosomal-recessive recurrence-risk counseling (25% per pregnancy) applies once both parental carrier variants are confirmed.
• Prenatal/preimplantation testing: Once a familial variant is known (e.g., after an affected child), prenatal diagnosis or preimplantation genetic testing could theoretically be offered for future pregnancies, per standard practice for known de novo monogenic disorders — no RHOBTB2-specific prenatal testing program was documented in the sources reviewed.
• Screening: No population or newborn screening program exists or is anticipated for this ultra-rare disorder.

14. Other Species / Natural Disease

No naturally occurring RHOBTB2-associated disease in non-human species (companion animals, livestock, wildlife) was identified in this search — no OMIA (Online Mendelian Inheritance in Animals) entry or veterinary case report surfaced. This appears to be a human-genetics-delineated disorder without a described natural-disease veterinary correlate at this time. This gap should be explicitly noted as "not identified" rather than assumed absent, since OMIA was not directly queried in this session.

Orthology: The Drosophila melanogaster ortholog is RhoBTB (single fly gene corresponding to the mammalian RhoBTB1/2/3 subfamily), used extensively as the primary in vivo functional model (see §6, §15). No specific mouse, rat, zebrafish, or other vertebrate ortholog gene ID was independently retrieved in this session beyond the human/mouse Wikipedia infobox coordinates (mouse Rhobtb2 at chromosome 14, band 14 D2).

15. Model Organisms

Explicit modeling gap: As of the most recent review located, "no patient-variant animal models [e.g., knock-in mouse] have been generated" to study RHOBTB2-related neurodevelopmental disease in vivo in a mammalian system — the iPSC-neuron and Drosophila systems represent the current state of the art, with the mammalian (mouse knock-in) gap flagged as an open need in the field (Frontiers Pediatrics 2024).

Model limitations: The Drosophila system captures dosage-sensitive seizure/locomotor and dendritic phenotypes but cannot recapitulate human-specific cortical architecture or the AHC-like alternating-hemiplegia clinical phenomenon. iPSC-neuron patch-clamp captures single-cell excitability changes but not network-level or whole-organism seizure semiology. No model to date recapitulates the postnatal-microcephaly or the fever/trauma-triggered acute-encephalopathy phenotypes specifically.

Summary of Key Curation-Relevant Ontology Term Suggestions

• Gene/protein: HGNC:18756 (RHOBTB2); UniProt Q9BYZ6
• Disease: OMIM:618004 (DEE64); OMIM:607352 (gene locus entry) — MONDO ID should be independently confirmed
• HPO (partial): HP:0001250 (Seizure), HP:0001249 (Intellectual disability), HP:0005484 (Postnatal microcephaly), HP:0001252 (Hypotonia), HP:0001332 (Dystonia), HP:0001251 (Ataxia), HP:0002072 (Chorea), HP:0011722 (Drug-resistant seizures), HP:0001263 (Global developmental delay), HP:0006846 (episodic encephalopathy — verify exact term)
• GO (mechanism): GO:0043161 (proteasome-mediated ubiquitin-dependent protein catabolic process), GO:0031461 (cullin-RING ubiquitin ligase complex), GO:0000502 (proteasome complex)
• CL: CL:0000540 (neuron)
• UBERON: UBERON:0000955 (brain), UBERON:0002420 (basal ganglion), UBERON:0002037 (cerebellum)
• CHEBI (treatments): CHEBI:39867 (valproic acid), CHEBI:6437 (levetiracetam), CHEBI:9366 (topiramate), CHEBI:7824 (oxcarbazepine)
• NCIT (treatment action): NCIT:C15986 (Pharmacotherapy)

Notable Evidence Gaps / Caveats for Curators

1. gnomAD constraint metrics (pLI, LOEUF, missense-Z) could not be retrieved directly in this session — verify at gnomad.broadinstitute.org before curating population-constraint claims.
2. MONDO ID for DEE64 was not independently confirmed — verify at mondo.monarchinitiative.org.
3. Several full-text sources (OMIM full clinical synopsis, GIM 2023 full text, Epilepsia 2026 full text) returned HTTP 403 on direct fetch; the summaries above rely on search-engine-indexed excerpts and secondary citations (Frontiers Pediatrics 2024 review, GeneCards, Wikipedia) rather than full primary-text extraction — snippets used for KB curation should be independently re-verified against the cached/fetched primary abstract per dismech's evidence SOP before being committed as evidence.snippet values.
4. No OMIA veterinary/natural-disease entry was directly queried — treat "no natural disease in other species identified" as an evidence gap, not a confirmed negative.
5. Precise phenotype frequency percentages (e.g., % with each seizure type, exact sex ratio) should be pulled directly from the largest cohort study (Epilepsia 2026, 91 cases) once full-text access is available, as only fragmentary percentages were recoverable via search snippets in this session.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• DOI:10.3389/fped.2024.1448793 (abstract only): "from total lack of head control and inability to walk to walking with a broad-based or unsteady gait"
• Text part not found as substring: 'from total lack of head control and inability to walk to walking with a broad-based or unsteady gait' (note: only abstract available for DOI:10.3389/fped.2024.1448793, full text may contain this excerpt)